Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib monotherapy for advanced urological tumors
ChiCTR2200066704Phase 2Not yet recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib in renal cell carcinoma (RCC), transitional cell carcinoma (TCC) and prostate cancer (PCa) (3 cohorts), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: Progression-free survival. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
renal cell carcinoma (RCC)transitional cell carcinoma (TCC)prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2200066704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066704.